Table 2.
Current study | Zarifian et al. (metaanalysis) [16] | Li et al. [20] | Wu et al. [21] | Pakdemirli et al. [22] | Wang et al. [23] | Tabatabaei et al. [24] | Werberich et al. [25] | |
---|---|---|---|---|---|---|---|---|
Number of patients | (n=414) | (n=9907) | (n=83) | (n=80) | (n=18) | (n=93) | (n=120) | (n=48) |
Pleural thickening and/or effusion | 16.9 | 5345–741 (13.8%) | 8.4 | 6 | 88 | 31.1 | 16.6 | 4.2 |
Nodule | 5.7 | 2582–338 (13.1%) | 7.2 | – | 61 | 18.3 | 25 | 4.2 |
Reversed halo sign | 1.2 | – | – | – | 0 | 15.1 | 11.6 | 4.2 |
LAP | 2.1 | 3197–165 (5.1%) | 8.4 | 4 | 17 | 6.5 | 0 | 4.2 |
Pericardial effusion | 1.6 | – | 4.8 | 5 | – | – | – | 6.2 |
Subpleural line | 0.9 | – | 20.5 | 20 | 61 | – | – | 14.6 |
Subpleural sparing | 3.3 | – | – | – | 33 | – | 23.3 | 6.2 |
Spider web sign | 2.8 | – | 25.3 | 25 | – | – | – | – |
Air bubble sign | 13 (3.1%) | – | – | – | – | 12.9 | – | 37.5 |
Tree-in-bud | 4 (0.9%) | – | – | – | 6 | 3.2 | 0 | – |
Central and/or | 1.9 | 2160–131 (6.1%) | – | 4 | 11 | – | 2.1 | |
peribronchovascular involvement | ||||||||
Isolated upper lobe involvement | 3.8 | – | – | – | 0 | – | – | 10.4 |
LAP: Lymphadenopathy.